Can I contribute to / participate in the TherVacB clinical trial as a Hepatitis B patient?
People with virological and host parameters that meet the inclusion criteria can join the clinical trial which allows to enrol around 90 participants in Europe and 20-30 in Tanzania / Africa.
In this clinical trial, modifications of the TherVacB hepatitis B vaccine shall be tested for safety and tolerability and will be compared to define optimal efficacy in patients.
Our TherVacB study sites across Europe and in eastern Africa have long-standing experience in clinical hepatitis B research and service. TherVacB study physicians are experts in the treatment of viral hepatitis.
If you are interested in participating in the TherVacB clinical study, please contact us. Just mark the checkbox and we will get in touch.
There are quite a few other ongoing studies on compounds in development for chronic hepatitis B and HBV cure. If you are interested, check out further details here.
ROYAL FREE LONDON NHS FOUNDATION TRUST
|Pond St, Hampstead, London NW3 2QG, UK|
Klinikum Rechts der Isar der Technischen Universität München
|Ismaninger Str. 22, 81675 München, Germany|
Azienda Ospedaliero- Universitaria di Parma
|Viale Antonio Gramsci, 14, 43126 Parma PR, Italy|
|Martinistraße 52, 20251 Hamburg, Germany|
Fundació Clínic per a la Recerca Biomèdica
|Carrer del Rosselló, 149, 08036 Barcelona, Spain|
Barts Health NHS Trust
|Whitechapel Rd, Whitechapel, London E1 1FR, UK|
Medizinische Hochschule Hannover
|Carl-Neuberg-Straße 1, 30625 Hannover, Germany|
NIMR-Mbeya Medical Research Center
|Hospital Hill Rd, Mbeya, Tanzania|
When will the clinical trial start?
The TherVacB clinical trial is replanned to start in January 2024.